BRPI0414323A - compostos que modulam crescimento neuronal e seus usos - Google Patents

compostos que modulam crescimento neuronal e seus usos

Info

Publication number
BRPI0414323A
BRPI0414323A BRPI0414323-0A BRPI0414323A BRPI0414323A BR PI0414323 A BRPI0414323 A BR PI0414323A BR PI0414323 A BRPI0414323 A BR PI0414323A BR PI0414323 A BRPI0414323 A BR PI0414323A
Authority
BR
Brazil
Prior art keywords
growth
compounds
nervous system
central nervous
neuronal growth
Prior art date
Application number
BRPI0414323-0A
Other languages
English (en)
Inventor
Patrick Doherty
Gareth Williams
Original Assignee
Wyeth Corp
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, King S College London filed Critical Wyeth Corp
Publication of BRPI0414323A publication Critical patent/BRPI0414323A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSTOS QUE MODULAM CRESCIMENTO NEURONAL E SEUS USOS". A presente invenção refere-se a peptídeos cíclicos e miméticos de peptídeo que são providos que se ligam a elou modulam atividades associadas com receptores de Trk, incluindo processos associados com o crescimento e reparo do sistema nervoso central (por exemplo, crescimento e sobrevivência neuronal, crescimento axonal, desenvolvimento de neurito e plasticidade sináptica). Peptídeos Cíclicos e miméticos de peptídeos também são providos que bloqueiam ou reduzem o efeito de outros fatores que inibem crescimento e/ou reparo do sistema nervoso central. Composições farmacêuticas e outras formulações compreendendo estes compostos são providas. Em adição, a invenção provê processos para uso de peptídeos cíclicos e miméticos de peptídeos para modulação de atividades mediadas por Trk, incluindo processos tais como crescimento, sobrevivência e recuperação neuronal, crescimento axonal, desenvolvimento de neurito, e plasticidade sináptica. Ainda, a invenção provê processos para promoção de crescimento de neurónio de sistema nervoso central (SNC) através de administração de um agente de ligação de receptor de p75.
BRPI0414323-0A 2003-09-10 2004-09-10 compostos que modulam crescimento neuronal e seus usos BRPI0414323A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50186403P 2003-09-10 2003-09-10
US55989804P 2004-04-05 2004-04-05
US60318704P 2004-08-20 2004-08-20
PCT/US2004/029888 WO2005025514A2 (en) 2003-09-10 2004-09-10 Compounds that modulate neuronal growth and their uses

Publications (1)

Publication Number Publication Date
BRPI0414323A true BRPI0414323A (pt) 2006-11-07

Family

ID=34317473

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414323-0A BRPI0414323A (pt) 2003-09-10 2004-09-10 compostos que modulam crescimento neuronal e seus usos

Country Status (7)

Country Link
US (1) US7196061B2 (pt)
EP (2) EP2438925A3 (pt)
JP (2) JP4944611B2 (pt)
AU (1) AU2004272107B2 (pt)
BR (1) BRPI0414323A (pt)
CA (1) CA2535279A1 (pt)
WO (1) WO2005025514A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
WO2006130781A2 (en) * 2005-06-01 2006-12-07 The Scripps Research Institute Crystal of a cytochrome-ligand complex and methods of use
JP2010509645A (ja) 2006-11-03 2010-03-25 トラスティーズ オブ タフツ カレッジ ナノパターンが形成されたバイオポリマー光学デバイスおよびその製造方法
EP2107964B1 (en) 2006-11-03 2016-08-31 Trustees of the Tufts College Biopolymer optical waveguide and method of manufacturing the same
WO2008127402A2 (en) * 2006-11-03 2008-10-23 Trustees Of Tufts College Biopolymer sensor and method of manufacturing the same
JP2011231085A (ja) * 2010-04-30 2011-11-17 Osaka Prefecture Univ 環状ペプチド
WO2016146730A1 (en) * 2015-03-19 2016-09-22 Neuheart S.R.L. PEPTIDES HAVING TrkA-RECEPTOR-AGONISTIC ACTIVITY OR HAVING NGF-ANTAGONISTIC ACTIVITY
JP7230197B2 (ja) * 2019-06-11 2023-02-28 富士フイルム株式会社 環状ペプチド、細胞足場材、細胞分離材、及び、培地
WO2021256619A1 (ko) * 2020-06-18 2021-12-23 연세대학교 산학협력단 시냅스 가소성 조절 기능의 펩타이드를 포함하는 인지기능 장애 질환의 예방, 개선 또는 치료용 조성물
JPWO2022009992A1 (pt) * 2020-07-10 2022-01-13

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079600A (en) 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
US5364769A (en) 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB9402331D0 (en) 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5844092A (en) 1994-03-18 1998-12-01 Genentech, Inc. Human TRK receptors and neurotrophic factor inhibitors
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
PL330240A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods and compositions useful in inhibiting angiogenesis in which alphavbeta5 acts as intermediary
US6031072A (en) 1996-07-12 2000-02-29 Mcgill University Compounds and methods for modulating cell adhesion
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
WO2002003071A2 (en) * 2000-07-05 2002-01-10 Pangene Corporation Modulators of trk protein activity, compositions and uses

Also Published As

Publication number Publication date
EP1663276A4 (en) 2009-02-18
JP4944611B2 (ja) 2012-06-06
JP2011057685A (ja) 2011-03-24
AU2004272107B2 (en) 2011-04-07
CA2535279A1 (en) 2005-03-24
EP2438925A2 (en) 2012-04-11
WO2005025514A2 (en) 2005-03-24
EP2438925A3 (en) 2012-08-29
US7196061B2 (en) 2007-03-27
JP2007505145A (ja) 2007-03-08
EP1663276A2 (en) 2006-06-07
WO2005025514A3 (en) 2005-08-11
US20050164920A1 (en) 2005-07-28
AU2004272107A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
BRPI0407293A (pt) Resposta duradoura da célula t
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BRPI0417959A (pt) anticorpo ou fragmento funcional deste, composição farmcêutica, método para tratamento ou profilaxia de acidente vascular cerebral e outras doenças/distúrbios neurológicos em um ser humano, uso de um anticorpo anti-nogo, e, métodos para inibir a neurodegeneração e/ou promover a recuperação funcional em um paciente humano, para promover o crescimento axonal, para produzir um anticorpo anti-nogo e para produzir uma composição farmacêutica intravenosamente administrável
BRPI0508820B8 (pt) compostos moduladores de receptor de opióide e composição que os compreende
BRPI0414323A (pt) compostos que modulam crescimento neuronal e seus usos
BR0113637A (pt) Composto, processo para a preparação desse composto, composição farmacêutica que compreende o mesmo, utilização do composto, processo para o tratamento e/ou profilaxia de enfermidade que estão associadas com a atividade de receptor melanocortin-4
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
BRPI0411505A (pt) uso de um composto, método para modular a resposta imune de um indivìduo, composição farmacêutica, vacina, complexo, e, kit para a captura de uma molécula biologicamente ativa
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
BR0213877A (pt) Compostos orgânicos
BRPI0507489A (pt) anticorpos humanos de anti-cd38 e para os seus usos
ES2154167B1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
ATE432291T1 (de) Kdr-peptide und diese enthaltende impfstoffe
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69733272D1 (de) N-(aryl/heteroarylacetyl)aminosäureester, diese enthaltende pharmazeutische zusammensetzungen und methoden zur inhibierung der beta-amyloidfreisetzung und/oder deren synthese unter verwendung dieser verbindungen
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE456953T1 (de) Behandlung von amyotrophischer lateralsklerose mit pyrimethamin und analoga
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
BR9811923A (pt) Compostos possuindo atividade neuronal
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
BRPI0616936B8 (pt) composição farmacêutica
BRPI0518062A (pt) uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
ATE475408T1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2323 DE 14-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.